Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday

Inozyme Pharma (NASDAQ:INZY - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Inozyme Pharma Stock Up 33.9 %

Shares of INZY traded up $0.41 during mid-day trading on Friday, hitting $1.62. 8,063,532 shares of the company's stock were exchanged, compared to its average volume of 493,052. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a twelve month low of $0.72 and a twelve month high of $6.24. The firm has a fifty day moving average of $1.01 and a two-hundred day moving average of $2.09. The stock has a market cap of $104.59 million, a price-to-earnings ratio of -1.04 and a beta of 1.35.

Wall Street Analyst Weigh In

A number of research analysts recently commented on INZY shares. Wedbush restated an "outperform" rating and issued a $7.00 target price (down from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Piper Sandler reduced their price objective on shares of Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. Raymond James lowered their target price on shares of Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 12th. Wells Fargo & Company cut their price objective on Inozyme Pharma from $14.00 to $11.00 and set an "overweight" rating for the company in a report on Monday, January 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Inozyme Pharma in a report on Thursday, April 10th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $14.63.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.